Summary

טיפול במומי Osteochondral במפרק הברך של הארנב על ידי השתלה של תאי גזע mesenchymal אלוגנאית בקרישי הפיברין

Published: May 21, 2013
doi:

Summary

טכניקה ניסויית לטיפול בפגמי osteochondral במפרק הברך של הארנב מתוארת. ההשתלה של תאי גזע מזנכימיים אלוגניות לפגמי osteochondral מספקת פיתוח מבטיח בתחום הנדסת רקמות. הכנת הפיברין-תא קרישים<em> במבחנה</em> מציע שיטה סטנדרטית להשתלה.

Abstract

The treatment of osteochondral articular defects has been challenging physicians for many years. The better understanding of interactions of articular cartilage and subchondral bone in recent years led to increased attention to restoration of the entire osteochondral unit. In comparison to chondral lesions the regeneration of osteochondral defects is much more complex and a far greater surgical and therapeutic challenge. The damaged tissue does not only include the superficial cartilage layer but also the subchondral bone. For deep, osteochondral damage, as it occurs for example with osteochondrosis dissecans, the full thickness of the defect needs to be replaced to restore the joint surface 1. Eligible therapeutic procedures have to consider these two different tissues with their different intrinsic healing potential 2. In the last decades, several surgical treatment options have emerged and have already been clinically established 3-6.

Autologous or allogeneic osteochondral transplants consist of articular cartilage and subchondral bone and allow the replacement of the entire osteochondral unit. The defects are filled with cylindrical osteochondral grafts that aim to provide a congruent hyaline cartilage covered surface 3,7,8. Disadvantages are the limited amount of available grafts, donor site morbidity (for autologous transplants) and the incongruence of the surface; thereby the application of this method is especially limited for large defects.

New approaches in the field of tissue engineering opened up promising possibilities for regenerative osteochondral therapy. The implantation of autologous chondrocytes marked the first cell based biological approach for the treatment of full-thickness cartilage lesions and is now worldwide established with good clinical results even 10 to 20 years after implantation 9,10. However, to date, this technique is not suitable for the treatment of all types of lesions such as deep defects involving the subchondral bone 11.

The sandwich-technique combines bone grafting with current approaches in Tissue Engineering 5,6. This combination seems to be able to overcome the limitations seen in osteochondral grafts alone. After autologous bone grafting to the subchondral defect area, a membrane seeded with autologous chondrocytes is sutured above and facilitates to match the topology of the graft with the injured site. Of course, the previous bone reconstruction needs additional surgical time and often even an additional surgery. Moreover, to date, long-term data is missing 12.

Tissue Engineering without additional bone grafting aims to restore the complex structure and properties of native articular cartilage by chondrogenic and osteogenic potential of the transplanted cells. However, again, it is usually only the cartilage tissue that is more or less regenerated. Additional osteochondral damage needs a specific further treatment. In order to achieve a regeneration of the multilayered structure of osteochondral defects, three-dimensional tissue engineered products seeded with autologous/allogeneic cells might provide a good regeneration capacity 11.

Beside autologous chondrocytes, mesenchymal stem cells (MSC) seem to be an attractive alternative for the development of a full-thickness cartilage tissue. In numerous preclinical in vitro and in vivo studies, mesenchymal stem cells have displayed excellent tissue regeneration potential 13,14. The important advantage of mesenchymal stem cells especially for the treatment of osteochondral defects is that they have the capacity to differentiate in osteocytes as well as chondrocytes. Therefore, they potentially allow a multilayered regeneration of the defect.

In recent years, several scaffolds with osteochondral regenerative potential have therefore been developed and evaluated with promising preliminary results 1,15-18. Furthermore, fibrin glue as a cell carrier became one of the preferred techniques in experimental cartilage repair and has already successfully been used in several animal studies 19-21 and even first human trials 22.

The following protocol will demonstrate an experimental technique for isolating mesenchymal stem cells from a rabbit’s bone marrow, for subsequent proliferation in cell culture and for preparing a standardized in vitro-model for fibrin-cell-clots. Finally, a technique for the implantation of pre-established fibrin-cell-clots into artificial osteochondral defects of the rabbit’s knee joint will be described.

Protocol

הכנת א ארנב תורם לבידוד של תאי גזע mesenchymal (חדר ניתוח) תאים מבודדים מזכר לבן (NZW) ארנבי ניו זילנד בגיל 4 חודשים וכ 3 ק"ג משקל גוף. לגרום הרדמה פרופופול על ידי (10 מ"ג / ק"ג משקל הגוף ד) ותקריב ע…

Representative Results

הטכניקה כירורגית תאר מאפשרת בידוד מוצלח והשתלה של תאי גזע מזנכימיים אלוגניות לפגם osteochondral מלאכותי. ההתקנה הניסיונית הביאה לשילוב מוצלח של השתל לתוך הסחוס שמסביב. הפגם היה מלא על ידי רקמת תיקון עם מאפיינים דומים biomechanical ועמידות ד?…

Discussion

בשנים האחרונות, את האפשרות של טיפול במומים מורכבים מפרק osteochondral – כגון אלה הנובעים מdissecans osteochondritis, נמק וטראומה – עם הנדסת רקמות גישות הפכה ליותר ויותר אטרקטיבי. בגופים פתולוגיים שהוזכרו קודם לכן, נזק לרקמות משתרעת על עצם subchondral וכוללת שתי רקמות המתאפיינות ביכולות ריפו…

Disclosures

The authors have nothing to disclose.

Acknowledgements

פרויקט זה מומן על ידי אגודת המחקר הגרמני (מענק HE 4578/3-1) וחלקו על ידי האיחוד האירופי FP7-הפרויקט "גמבה" NMP3-SL-2010-245,993.

Materials

Name of reagent/equipment Company Catalogue Number Comments
DMEM Biochrom AG F 0415  
FCS PAN Biotech GmbH 0401  
Propofol Fresenius Kabi    
Penicillin/Streptomycin Biochrom AG A 2210 1,000 units/10 μg/μl in 0.9% NaCl
PBS Dulbecco (1X) Biochrom AG L1815  
Ethanol (70%) Merck KGaA 410230  
Trypan Blue Solution (0.4%) Sigma-Aldrich T8154  
Biocoll Separation Sol. Biochrom AG L6115 Isotonic solution Density: 1,077 g/ml
Trypsin-EDTA 0.05% Invitrogen GmbH 25300-054  
Fentanyl DeltaSelectGmBH 1819340  
NaCl solution (0.9%) BBraun 8333A193  
Syringes (Injekt) BBraun 4606108V  
Needles (Sterican) BBraun 4657519  
Forceps (blunt/sharp) Aesculap    
Scissors Aesculap    
Scalpels Feather Safety Razor Co 02.001.30.022  
Pipettes research Eppendorf    
Bone Cutter Aesculap    
Tissue culture dishes 100 mm/150 mm TPP AG 93100/93150 Growth area 60.1 mm2/147.8 mm2
Tissue culture flasks 25/75 mm2 TPP AG 90025/90075 25 mm2, 75 mm2
Centrifuge Tubes (50 ml) TPP AG 91050 Gamma-sterilized
CO2 Incubator Forma Scientific Inc.    
Cell culture laminar flow hood Hera Safe Heraeus Instruments    
Sterile saw Aesculap    
Centrifuge Megafuge 2.0 R Heraeus Instruments    
Hemocytometer Brand GmbH+Co KG 717810 Neubauer
Air operated power drill Aesculap    
TISSUCOL-Kit 1.0 ml Immuno Baxter 2546648  
Fibers (4-0 Monocryl, 4-0 Vicryl) Ethicon    
Spray dressing (OpSite) Smith&Nephew 66004978 Permeable for water vapor

References

  1. Kon, E., et al. Novel nano-composite multilayered biomaterial for osteochondral regeneration: a pilot clinical trial. The American Journal of Sports Medicine. 39, 1180-1190 (2011).
  2. Kon, E., et al. Orderly osteochondral regeneration in a sheep model using a novel nano-composite multilayered biomaterial. Journal of Orthopaedic Research: Official Publication of the Orthopaedic Research Society. 28, 116-124 (2010).
  3. Hangody, L., et al. Autologous osteochondral grafting–technique and long-term results. Injury. 39, 32-39 (2008).
  4. Marcacci, M., et al. Arthroscopic autologous osteochondral grafting for cartilage defects of the knee: prospective study results at a minimum 7-year follow-up. The American Journal of Sports Medicine. 35, 2014-2021 (2007).
  5. Ochs, B. G., et al. Remodeling of articular cartilage and subchondral bone after bone grafting and matrix-associated autologous chondrocyte implantation for osteochondritis dissecans of the knee. The American Journal of Sports Medicine. 39, 764-773 (2011).
  6. Aurich, M., et al. Autologous chondrocyte transplantation by the sandwich technique. A salvage procedure for osteochondritis dissecans of the knee. Unfallchirurg. 110, 176-179 (2007).
  7. Williams, R. J., Ranawat, A. S., Potter, H. G., Carter, T., Warren, R. F. Fresh stored allografts for the treatment of osteochondral defects of the knee. The Journal of Bone and Joint Surgery. American Volume. 89, 718-726 (2007).
  8. Szerb, I., Hangody, L., Duska, Z., Kaposi, N. P. Mosaicplasty: long-term follow-up. Bull. Hosp. Jt. Dis. 63, 54-62 (2005).
  9. Brittberg, M., et al. Treatment of deep cartilage defects in the knee with autologous chondrocyte transplantation. N. Engl. J. Med. 331, 889-895 (1994).
  10. Peterson, L., Vasiliadis, H. S., Brittberg, M., Lindahl, A. Autologous chondrocyte implantation: a long-term follow-up. Am. J. Sports Med. 38, 1117-1124 (2010).
  11. Gomoll, A. H., et al. The subchondral bone in articular cartilage repair: current problems in the surgical management. Knee Surg. Sports Traumatol. Arthrosc. 18, 434-447 (2010).
  12. Steinhagen, J., et al. Treatment of osteochondritis dissecans of the femoral condyle with autologous bone grafts and matrix-supported autologous chondrocytes. Int. Orthop. 34, 819-825 (2010).
  13. Guo, X., et al. Repair of large articular cartilage defects with implants of autologous mesenchymal stem cells seeded into beta-tricalcium phosphate in a sheep model. Tissue Eng. 10, 1818-1829 (2004).
  14. Centeno, C. J., et al. Increased knee cartilage volume in degenerative joint disease using percutaneously implanted, autologous mesenchymal stem cells. Pain Physician. 11, 343-353 (2008).
  15. Niederauer, G. G., et al. Evaluation of multiphase implants for repair of focal osteochondral defects in goats. Biomaterials. 21, 2561-2574 (2000).
  16. Nagura, I., et al. Repair of osteochondral defects with a new porous synthetic polymer scaffold. J. Bone. Joint Surg. Br. 89, 258-264 (2007).
  17. Schlichting, K., et al. Influence of scaffold stiffness on subchondral bone and subsequent cartilage regeneration in an ovine model of osteochondral defect healing. The American Journal of Sports Medicine. 36, 2379-2391 (2008).
  18. Schagemann, J. C., et al. Cell-laden and cell-free biopolymer hydrogel for the treatment of osteochondral defects in a sheep model. Tissue Engineering. Part A. 15, 75-82 (2009).
  19. Vogt, S., et al. The influence of the stable expression of BMP2 in fibrin clots on the remodelling and repair of osteochondral defects. Biomaterials. 30, 2385-2392 (2009).
  20. Schillinger, U., et al. A fibrin glue composition as carrier for nucleic acid vectors. Pharm. Res. 25, 2946-2962 (2008).
  21. Ahmed, T. A., Giulivi, A., Griffith, M., Hincke, M. Fibrin glues in combination with mesenchymal stem cells to develop a tissue-engineered cartilage substitute. Tissue Engineering. Part A. 17, 323-335 (2011).
  22. Haleem, A. M., et al. The Clinical Use of Human Culture-Expanded Autologous Bone Marrow Mesenchymal Stem Cells Transplanted on Platelet-Rich Fibrin Glue in the Treatment of Articular Cartilage Defects: A Pilot Study and Preliminary Results. Cartilage. 1, 253-261 (2010).
  23. Pape, D., Filardo, G., Kon, E., van Dijk, C. N., Madry, H. Disease-specific clinical problems associated with the subchondral bone. Knee Surg Sports Traumatol. Arthrosc. 18, 448-462 (2010).
  24. Shirazi, R., Shirazi-Adl, A. Computational biomechanics of articular cartilage of human knee joint: effect of osteochondral defects. Journal of Biomechanics. 42, 2458-2465 (2009).
  25. Jorgensen, C., Gordeladze, J., Noel, D. Tissue Engineering through autologous mesenchymal stem cells. Curr. Opin. Biotechnol. 15, 406-410 (2004).
  26. Chen, F. H., Tuan, R. S. Mesenchymal stem cells in arthritic diseases. Arthritis Res. Ther. 10, 223 (2008).
  27. Le Blanc, K., Tammik, C., Rosendahl, K., Zetterberg, E., Ringden, O. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp. Hematol. 31, 890-896 (2003).
check_url/4423?article_type=t

Play Video

Cite This Article
Berninger, M. T., Wexel, G., Rummeny, E. J., Imhoff, A. B., Anton, M., Henning, T. D., Vogt, S. Treatment of Osteochondral Defects in the Rabbit’s Knee Joint by Implantation of Allogeneic Mesenchymal Stem Cells in Fibrin Clots. J. Vis. Exp. (75), e4423, doi:10.3791/4423 (2013).

View Video